A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee
← catalyst calendarNCT03588975 · readout ≤ 1,289 d
Sponsored by Vericel Corporation (industry) · VCEL — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
45estimated
Sites
12
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2018-10-24 | actual | When the study began enrolling |
| Primary completion | Feb 2030 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2030 | estimated | The whole study's end, after follow-up |
| First posted | 2018-07-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Chondral Defect
- Osteochondritis Dissecans (OCD)
- Articular Cartilage Defect
- Articular Cartilage Disorder of Knee
Interventions
- Biological: MACI
- Procedure: microfracture
Primary outcome
what the primary-completion date above is the date OFProportion of Participants Who Achieve ≥ 10-point Improvement From Baseline in KOOS-Child Pain and Function (Sports and Recreational Activities) Subscale Scores
measured Baseline and Week 104
Permalink · VCEL's whole pipeline · Catalyst calendar · Every registered study · What changed